Combination Therapy with Gallium Protoporphyrin and Gallium Nitrate Exhibits Enhanced Antimicrobial Activity In Vitro and In Vivo against Methicillin-Resistant Staphylococcus aureus

IF 4.5 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Seoung-ryoung Choi, Geoffrey A. Talmon, Kenneth Hearne, Jennifer Woo, Vu L. Truong, Bradley E. Britigan and Prabagaran Narayanasamy*, 
{"title":"Combination Therapy with Gallium Protoporphyrin and Gallium Nitrate Exhibits Enhanced Antimicrobial Activity In Vitro and In Vivo against Methicillin-Resistant Staphylococcus aureus","authors":"Seoung-ryoung Choi,&nbsp;Geoffrey A. Talmon,&nbsp;Kenneth Hearne,&nbsp;Jennifer Woo,&nbsp;Vu L. Truong,&nbsp;Bradley E. Britigan and Prabagaran Narayanasamy*,&nbsp;","doi":"10.1021/acs.molpharmaceut.3c00223","DOIUrl":null,"url":null,"abstract":"<p >There is a major need for the development of new therapeutics to combat antibiotic-resistant <i>Staphylococcus aureus</i>. Recently, gallium (Ga)-based complexes have shown promising antimicrobial effects against various bacteria, including multidrug-resistant organisms, by targeting multiple heme/iron-dependent metabolic pathways. Among these, Ga protoporphyrin (GaPP) inhibits bacterial growth by targeting heme pathways, including aerobic respiration. Ga(NO<sub>3</sub>)<sub>3</sub>, an iron mimetic, disrupts elemental iron pathways. Here, we demonstrate the enhanced antimicrobial activity of the combination of GaPP and Ga(NO<sub>3</sub>)<sub>3</sub> against methicillin-resistant <i>S. aureus</i> (MRSA) under iron-limited conditions, including small colony variants (SCV). This therapy demonstrated significant antimicrobial activity without inducing slow-growing SCV. We also observed that the combination of GaPP and Ga(NO<sub>3</sub>)<sub>3</sub> inhibited the MRSA catalase but not above that seen with Ga(NO<sub>3</sub>)<sub>3</sub> alone. Neither GaPP nor Ga(NO<sub>3</sub>)<sub>3</sub> alone or their combination inhibited the dominant superoxide dismutase expressed (SodA) under the iron-limited conditions examined. Intranasal administration of the combination of the two compounds improved drug biodistribution in the lungs compared to intraperitoneal administration. In a murine MRSA lung infection model, we observed a significant increase in survival and decrease in MRSA lung CFUs in mice that received combination therapy with intranasal GaPP and Ga(NO<sub>3</sub>)<sub>3</sub> compared to untreated control or mice receiving GaPP or Ga(NO<sub>3</sub>)<sub>3</sub> alone. No drug-related toxicity was observed as assessed histologically in the spleen, lung, nasal cavity, and kidney for both single and repeated doses of 10 mg Ga /Kg of mice over 13 days. Our results strongly suggest that GaPP and Ga(NO<sub>3</sub>)<sub>3</sub> in combination have excellent synergism and potential to be developed as a novel therapy for infections with <i>S. aureus</i>.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"20 8","pages":"4058–4070"},"PeriodicalIF":4.5000,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.3c00223","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

There is a major need for the development of new therapeutics to combat antibiotic-resistant Staphylococcus aureus. Recently, gallium (Ga)-based complexes have shown promising antimicrobial effects against various bacteria, including multidrug-resistant organisms, by targeting multiple heme/iron-dependent metabolic pathways. Among these, Ga protoporphyrin (GaPP) inhibits bacterial growth by targeting heme pathways, including aerobic respiration. Ga(NO3)3, an iron mimetic, disrupts elemental iron pathways. Here, we demonstrate the enhanced antimicrobial activity of the combination of GaPP and Ga(NO3)3 against methicillin-resistant S. aureus (MRSA) under iron-limited conditions, including small colony variants (SCV). This therapy demonstrated significant antimicrobial activity without inducing slow-growing SCV. We also observed that the combination of GaPP and Ga(NO3)3 inhibited the MRSA catalase but not above that seen with Ga(NO3)3 alone. Neither GaPP nor Ga(NO3)3 alone or their combination inhibited the dominant superoxide dismutase expressed (SodA) under the iron-limited conditions examined. Intranasal administration of the combination of the two compounds improved drug biodistribution in the lungs compared to intraperitoneal administration. In a murine MRSA lung infection model, we observed a significant increase in survival and decrease in MRSA lung CFUs in mice that received combination therapy with intranasal GaPP and Ga(NO3)3 compared to untreated control or mice receiving GaPP or Ga(NO3)3 alone. No drug-related toxicity was observed as assessed histologically in the spleen, lung, nasal cavity, and kidney for both single and repeated doses of 10 mg Ga /Kg of mice over 13 days. Our results strongly suggest that GaPP and Ga(NO3)3 in combination have excellent synergism and potential to be developed as a novel therapy for infections with S. aureus.

Abstract Image

原卟啉镓和硝酸镓联合治疗体外和体内对耐甲氧西林金黄色葡萄球菌的抗菌活性增强
目前迫切需要开发新的治疗方法来对抗耐抗生素的金黄色葡萄球菌。最近,镓(Ga)基配合物通过靶向多种血红素/铁依赖的代谢途径,对多种细菌(包括多药耐药生物)显示出有希望的抗菌作用。其中,Ga原卟啉(GaPP)通过靶向血红素途径(包括有氧呼吸)抑制细菌生长。Ga(NO3)3,一种铁的模拟物,破坏元素铁的途径。在这里,我们证明了GaPP和Ga(NO3)3组合在铁限制条件下对耐甲氧西林金黄色葡萄球菌(MRSA)的抗菌活性增强,包括小菌落变异(SCV)。该疗法显示出显著的抗菌活性,而不会诱导生长缓慢的SCV。我们还观察到GaPP和Ga(NO3)3联合对MRSA过氧化氢酶的抑制作用,但不高于Ga(NO3)3单独作用。在铁限条件下,GaPP和Ga(NO3)3单独或联合均不能抑制显性超氧化物歧化酶的表达(SodA)。与腹腔内给药相比,这两种化合物的鼻内给药改善了药物在肺部的生物分布。在小鼠MRSA肺部感染模型中,我们观察到与未治疗的对照组或单独接受GaPP或Ga(NO3)3的小鼠相比,接受鼻内GaPP和Ga(NO3)3联合治疗的小鼠的存活率显著增加,MRSA肺部cfu显著降低。在13天的时间里,单次和多次给药10 mg Ga /Kg小鼠的脾脏、肺、鼻腔和肾脏均未观察到药物相关毒性。我们的研究结果强烈提示GaPP和Ga(NO3)3联合使用具有良好的协同作用,具有开发金黄色葡萄球菌感染新疗法的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Pharmaceutics
Molecular Pharmaceutics 医学-药学
CiteScore
8.00
自引率
6.10%
发文量
391
审稿时长
2 months
期刊介绍: Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development. Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信